tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of David Hoang, 13 are a BUY (56.52%), 8 are a HOLD (34.78%), 2 are a SELL (8.7%).
Analyst David Hoang, currently employed at CITI, carries an average stock price target met ratio of 32.78% that have a potential upside of 15.2% achieved within 82 days.
David Hoang’s has documented 46 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 08-Aug-2024.
Analyst best performing recommendations are on LBPH (LONGBOARD PHARMACEUTICALS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 12/13/2023. The price target of $113 was fulfilled within 27 days with a profit of $20.89 (22.68%) receiving and performance score of 8.4.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$16
$-0.7 (-4.19%)
$22
1 years 2 months 15 days ago
(05-Oct-2023)
1/2 (50%)
$0.05 (0.31%)
1
Buy
$15
$-1.7 (-10.18%)
$15
1 years 5 months 23 days ago
(27-Jun-2023)
2/2 (100%)
$9.77 (186.81%)
146
Buy
1 years 6 months 7 days ago
(13-Jun-2023)
1/2 (50%)
$88 (107.32%)
428
Buy
$5
$-11.7 (-70.06%)
1 years 9 months 7 days ago
(13-Mar-2023)
1/1 (100%)
$0.05 (1.01%)
1
Buy
$13
2 years 7 months 7 days ago
(13-May-2022)
1/2 (50%)
$-34.2 (-72.46%)
481
Which stock is David Hoang is most bullish on?
Which stock is David Hoang is most reserved on?
What Year was the first public recommendation made by David Hoang?
